2020
Anticoagulation in COVID-19: Effect of Enoxaparin, Heparin, and Apixaban on Mortality
Billett H, Reyes-Gil M, Szymanski J, Ikemura K, Stahl L, Lo Y, Rahman S, Gonzalez-Lugo J, Kushnir M, Barouqa M, Golestaneh L, Bellin E. Anticoagulation in COVID-19: Effect of Enoxaparin, Heparin, and Apixaban on Mortality. Thrombosis And Haemostasis 2020, 120: 1691-1699. PMID: 33186991, PMCID: PMC7869055, DOI: 10.1055/s-0040-1720978.Peer-Reviewed Original ResearchConceptsD-dimer levelsD-dimerProphylactic useDecreased mortalityHigher D-dimer levelsAssociated with decreased mortalityIntensive care unit admissionAssociated with disease severityAssociated with increased mortalityGlomerular filtration rateLogistic regression analysisEffect of enoxaparinProthrombotic parametersTransfusion requirementsAnticoagulant therapyUnit admissionFiltration rateCohort studyClinical trialsAnticoagulationApixabanOxygen saturationEnoxaparinIllness severityDisease severityImmune to addiction: the ethical dimensions of vaccines against substance abuse
Young M, Sisti D, Rimon-Greenspan H, Schwartz J, Caplan A. Immune to addiction: the ethical dimensions of vaccines against substance abuse. 2020, 91-94. DOI: 10.4324/9781003074984-6.Peer-Reviewed Original ResearchSubstance use disordersSubstance abuseCategories of immunotherapyEthical dimensionsEthical issuesAvailability of vaccinesParadigm caseProphylactic useImmunological interventionSuch vaccinesClinical investigationVaccineTherapeutic useCocaine addictionImmunotherapyDisordersIssuesAddictionEthicsSocioeconomic consequencesPromising advancesAbuseVaccinationMorphineTherapy
2019
Gottesfeld-Hohler Memorial Foundation Risk Assessment for Early-Onset Preeclampsia in the United States: Think Tank Summary.
Copel JA, Platt LD, Hobbins JC, Afshar Y, Grechukhina O, Mallampati D, Bromley B, Caughey AB, Grobman W, Han CS, Nicolaides K, Pettker C, Saade G, Sibai B, Simhan H, Sonek J, Werner E, Chescheir N. Gottesfeld-Hohler Memorial Foundation Risk Assessment for Early-Onset Preeclampsia in the United States: Think Tank Summary. Obstetrics And Gynecology 2019, 135: 36-45. PMID: 31809427, DOI: 10.1097/aog.0000000000003582.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsEarly-onset preeclampsiaSubstantial economic burdenCost-effectiveness dataAspirin prophylaxisNeonatal morbidityPreterm preeclampsiaProphylactic usePreventive strategiesEconomic burdenPreeclampsiaCurrent professional guidelinesRisk assessment strategiesRisk assessmentPractice changeDifferent assessment toolsSpecific knowledge gapsAspirinUnited StatesTarget populationConsequent interventionsFeasibility of implementationProfessional guidelinesAssessment toolAvailable literatureRisk
2018
Prevention of hemodialysis catheter infections: Ointments, dressings, locks, and catheter hub devices
Golestaneh L, Mokrzycki M. Prevention of hemodialysis catheter infections: Ointments, dressings, locks, and catheter hub devices. Hemodialysis International 2018, 22: s75-s82. PMID: 30411464, DOI: 10.1111/hdi.12703.Peer-Reviewed Original ResearchConceptsBlood stream infectionsAssociated with excess morbidityTunneled central venous cathetersTopical antimicrobial ointmentsCatheter lock solutionCentral venous catheterClinical practice guidelinesVenous cathetersProphylactic useProvision of hemodialysisHemodialysis cathetersAntimicrobial ointmentsOintment applicationHemodialysis populationExcess morbidityCatheterLock solutionsInfectionReduce infectionPractice guidelinesHemodialysisOintmentExit siteMortalityPrevention
2016
Impact of Treatment of Non-bleeding Complications of Cirrhosis on the Risk of Variceal Bleeding
Augustin S, Albillos A, Ripoll C, Abraldes J, Salerno F, Moreau R, Reiberger T, Garcia-Tsao G. Impact of Treatment of Non-bleeding Complications of Cirrhosis on the Risk of Variceal Bleeding. 2016, 341-353. DOI: 10.1007/978-3-319-23018-4_34.Peer-Reviewed Original ResearchHepatic venous pressure gradientVariceal hemorrhageVariceal bleedingPortal pressureAlpha-1 adrenergic antagonistNon-bleeding complicationsVenous pressure gradientPortal blood flowClinical trial recordsImpact of treatmentDecompensated cirrhosisOral anticoagulantsRefractory ascitesCirrhotic patientsClinical decompensationCohort studyArterial pressureVasoactive drugsRandomized trialsLarge trialsCardiac outputProphylactic useAdrenergic antagonistsClinical dataBlood flow
2013
Nanogel-based delivery of mycophenolic acid ameliorates systemic lupus erythematosus in mice
Look M, Stern E, Wang QA, DiPlacido LD, Kashgarian M, Craft J, Fahmy TM. Nanogel-based delivery of mycophenolic acid ameliorates systemic lupus erythematosus in mice. Journal Of Clinical Investigation 2013, 123: 1741-1749. PMID: 23454752, PMCID: PMC3613921, DOI: 10.1172/jci65907.Peer-Reviewed Original ResearchConceptsSystemic lupus erythematosusMedian survival timeMycophenolic acidLupus erythematosusImmune cellsLupus-prone NZB/W F1 miceNZB/W F1 miceSimilar therapeutic resultsW F1 miceSevere renal damageCD4 T cellsAntigen-presenting cellsLupus therapyRenal damageIL-12Immunosuppressant mycophenolic acidInflammatory cytokinesProphylactic useTherapeutic resultsF1 miceT cellsSurvival timeGreater dosesErythematosusImmunosuppression
2011
Antimalarial Agents
Parikh S, Lee M, Aweeka F. Antimalarial Agents. Infectious Disease 2011, 561-579. DOI: 10.1007/978-1-61779-213-7_16.Peer-Reviewed Original ResearchOld antimalarial drugMainstay of treatmentCases of malariaDrug-drug interactionsTreatment of malariaImportant infectious diseasesWorld Health OrganizationUncomplicated malariaArtemether-lumefantrinePharmacodynamic interactionsSulfadoxine-pyrimethamineACT drugsCombination therapyPartner drugsProphylactic useArtemisinin drugsDrug interactionsMalaria therapyDrug combinationsOld drugsComplex pharmacologyVirulent human malariaMalaria todayAntimalarial drugsACT exposure
2010
Detrimental Effect of the Proteasome Inhibitor, Bortezomib in Bacterial Superantigen- and Lipopolysaccharide-induced Systemic Inflammation
Tilahun A, Theuer J, Patel R, David C, Rajagopalan G. Detrimental Effect of the Proteasome Inhibitor, Bortezomib in Bacterial Superantigen- and Lipopolysaccharide-induced Systemic Inflammation. Molecular Therapy 2010, 18: 1143-1154. PMID: 20372109, PMCID: PMC2889741, DOI: 10.1038/mt.2010.53.Peer-Reviewed Original ResearchConceptsToxic shock syndromeStaphylococcal enterotoxin BNF-kappaB activationSystemic inflammationSerum levelsBacterial superantigensKappaB activationElevated TNF-alpha levelsTNF-alpha levelsAcute liver failureProteasome inhibitorsSevere systemic inflammationNuclear factor-kappaBSerum biochemical parametersTNF-alpha-induced cell deathSerum TNFLiver failureHistopathological findingsUntreated miceShock syndromeProphylactic useMurine modelImportant cytokineBortezomibFactor-kappaB
2005
Pharmacologic prophylaxis for postoperative atrial tachyarrhythmia in general thoracic surgery: Evidence from randomized clinical trials
Sedrakyan A, Treasure T, Browne J, Krumholz H, Sharpin C, van der Meulen J. Pharmacologic prophylaxis for postoperative atrial tachyarrhythmia in general thoracic surgery: Evidence from randomized clinical trials. Journal Of Thoracic And Cardiovascular Surgery 2005, 129: 997-1005. PMID: 15867772, DOI: 10.1016/j.jtcvs.2004.07.042.Peer-Reviewed Original ResearchMeSH KeywordsAdrenergic beta-AntagonistsAgedAmiodaroneAnti-Arrhythmia AgentsAtrial FibrillationAtrial FlutterCalcium Channel BlockersDigitalis GlycosidesEvidence-Based MedicineFemaleFlecainideHospital CostsHumansLength of StayMagnesiumMaleMiddle AgedMorbidityPostoperative ComplicationsPremedicationPreoperative CareRandomized Controlled Trials as TopicTachycardia, SupraventricularThoracic Surgical ProceduresTreatment OutcomeConceptsPostoperative atrial tachyarrhythmiasGeneral thoracic surgeryAtrial tachyarrhythmiasCalcium channel blockersRandomized clinical trialsThoracic surgeryClinical trialsSingle small trialLonger hospital stayUse of digitalisPossible adverse eventsFixed-effects modelAntiarrhythmic medicationsPharmacologic prophylaxisHospital stayProphylactic regimenAdverse eventsCommon complicationPulmonary edemaSignificant morbidityUnblinded trialCochrane DatabaseProphylactic useSmall trialsPlacebo controlUse of RNA Interference to Prevent Lethal Murine West Nile Virus Infection
Bai F, Wang T, Pal U, Bao F, Gould LH, Fikrig E. Use of RNA Interference to Prevent Lethal Murine West Nile Virus Infection. The Journal Of Infectious Diseases 2005, 191: 1148-1154. PMID: 15747251, DOI: 10.1086/428507.Peer-Reviewed Original ResearchConceptsWest Nile virusNile virusWest Nile virus infectionWest Nile virus replicationInjection 24 hAdministration of siRNAsIntraperitoneal inoculumViral loadProphylactic useFatal encephalitisLethal infectionVirus infectionViral infectionVirus replicationPartial protectionInfectionVirusMicePresent studyRNA interferenceEncephalitisSiRNAsAdministration
2004
Guidelines for the appropriate use of non‐steroidal anti‐inflammatory drugs, cyclo‐oxygenase‐2‐specific inhibitors and proton pump inhibitors in patients requiring chronic anti‐inflammatory therapy
Dubois RW, Melmed GY, Henning JM, Laine L. Guidelines for the appropriate use of non‐steroidal anti‐inflammatory drugs, cyclo‐oxygenase‐2‐specific inhibitors and proton pump inhibitors in patients requiring chronic anti‐inflammatory therapy. Alimentary Pharmacology & Therapeutics 2004, 19: 197-208. PMID: 14723611, DOI: 10.1111/j.0269-2813.2004.01834.x.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsProton pump inhibitorsCost of NSAIDsPump inhibitorsGastrointestinal eventsChronic anti-inflammatory therapyRAND/UCLA Appropriateness MethodNon-steroidal anti-inflammatory drugsAnti-inflammatory therapyAnti-inflammatory drugsDrug treatment strategiesCommunity-based settingsCardiovascular riskProphylactic useAppropriateness MethodTreatment strategiesLower riskNSAIDsPatientsClinical scenariosAspirinAppropriate useInhibitorsRiskCare entitiesLiterature review
1999
Optimal dosing and triggers for prophylactic use of platelet transfusions
Rinder H, Arbini A, Snyder E. Optimal dosing and triggers for prophylactic use of platelet transfusions. Current Opinion In Hematology 1999, 6: 437. PMID: 10546800, DOI: 10.1097/00062752-199911000-00015.Peer-Reviewed Original ResearchConceptsProphylactic platelet transfusionsPlatelet transfusionsPlatelet transfusion guidelinesPlatelet transfusion practicesPlatelet transfusion supportAdequate platelet inventoryTransfusion intervalTransfusion guidelinesTransfusion supportMyeloablative therapyOptimal dosingTransfusion practiceProphylactic useThrombocytopenic patientsOutpatient supportPatient outcomesInpatient settingPlatelet dosePlatelet dosesTransfusionSmall dosesPlatelet inventoryPatientsDosesRecent studies
1992
Prophylactic Use of Apraclonidine for Intraocular Pressure Increase After Nd:YAG Capsulotomies
Silverstone D, Brint S, Olander K, Taylor R, McCarty G, deFaller J, Burk L. Prophylactic Use of Apraclonidine for Intraocular Pressure Increase After Nd:YAG Capsulotomies. American Journal Of Ophthalmology 1992, 113: 401-405. PMID: 1348396, DOI: 10.1016/s0002-9394(14)76162-8.Peer-Reviewed Original ResearchConceptsVehicle-treated groupIntraocular pressurePosterior capsulotomyYAG laser posterior capsulotomyIncidence of increaseMean maximal changeMasked clinical trialIntraocular pressure increaseLaser posterior capsulotomyYAG posterior capsulotomyTreatment armamentariumProphylactic effectYAG capsulotomyProphylactic useAdverse reactionsClinical trialsVisual functionRelative safetyCapsulotomyMaximal changeApraclonidineGroupMulticenterPatientsArmamentariumFulminant Epstein‐Barr virus‐associated post‐transplant lymphoproliferative disorders following OKT3 therapy
Canfield C, Hudnall S, Colonna J, Busuttil R, Wilkinson A, Danovitch G, Shaked A, Goldstein L, Rosenthal J. Fulminant Epstein‐Barr virus‐associated post‐transplant lymphoproliferative disorders following OKT3 therapy. Clinical Transplantation 1992, 6: 1-9. DOI: 10.1111/j.1399-0012.1992.tb00580.x.Peer-Reviewed Original ResearchPost-transplant lymphoproliferative disorderLymphoproliferative disordersEpstein-Barr virus-associated post-transplant lymphoproliferative disorderAssociated with Epstein-Barr virusOKT3 monoclonal antibody therapySequelae of immunosuppressionWithdrawal of immunosuppressionMonoclonal antibody therapyPeripheral blood smearEpstein-Barr virusOKT3 therapyAtypical lymphocytesMalignant lymphomaAntibody therapyClinical spectrumProphylactic useImmunosuppressionOKT3Medical CenterBlood smearsAcyclovirTherapyDisordersLymphomaLymphocytes
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply